On Tuesday, Advicenne announced a 13% increase in sales for fiscal year 2022, thanks in particular to a significant acceleration in growth in the second half of the year.

This morning, the pharmaceutical company specializing in the treatment of rare kidney diseases reported annual revenues of 3.7 million euros, compared with 3.3 million euros the previous year.

Annual growth was driven mainly by sales of Sibnayal, which came to 1.4 million euros in 2022, up 40% on the previous year.

Sibnayal, a fixed combination of potassium citrate and potassium bicarbonate, is indicated for the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents and children.

In its press release, Advicenne notes that the second half of 2022 saw a marked acceleration in the growth of Sibnayal sales, which jumped 70% in the second half of the year thanks to the direct launch in the UK.

The company also claims to have benefited from the impact of various partnerships signed in Europe and the development of therapeutic management of ATRd patients in France.

In a reaction note, analysts at Invest Securities highlight annual sales that are "still at modest levels", which translated into a decline of over 6% in the share price on Tuesday on the Paris Bourse.

Copyright (c) 2023 CercleFinance.com. All rights reserved.